NCT02474953已完成1 期
A Randomized, Double-blind, Crossover Study to Compare the Pharmacokinetic Profile of a Proprietary Curcumin Formulation to a Comparator Curcumin Product
适应症
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 12
- 试验地点
- 1
- 主要终点
- Curcumin AUC
研究概览
简要总结
This study is investigating the pharmacokinetic profile (i.e. the way the product is processed by the body) of a proprietary curcumin formulation compared to an unformulated curcumin product. Subjects will take a single dose of either the proprietary formulation or comparator product and the blood levels of curcumin and curcumin metabolites will be measured over a period of 48 hours.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Basic Science
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Male and females 18-45 years of age
- •If female, subject is not of child bearing potential, which is defined as females who have had a hysterectomy or oophorectomy, bilateral tubal ligation or are post-menopausal (natural or surgically with > 1 year since last menstruation) OR
- •Females of childbearing potential must agree to use a medically approved method of birth control and have a negative urine pregnancy test result. Acceptable methods of birth control include:
- •Hormonal contraceptives including oral contraceptives, hormone birth control patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System)
- •Double-barrier method
- •Non-hormonal intrauterine devices
- •Vasectomy of partner
- •BMI 18-29.9 kg/m2 (±1 kg/m2)
- •Healthy as determined by laboratory results and medical history
- •Agrees to maintain current level of physical activity throughout the study
- •Agree to avoid using black or white pepper, turmeric, curcumin or curry in the preparation of food for 7 days prior to randomization and throughout the study period.
- •Agree to avoid Indian and Thai cuisines for the period of the study
- •Agree to avoid food with yellow dye #E100
- •Agrees to avoid alcohol, caffeine 12 hours and grapefruit and grapefruit juice 48 hours prior to baseline and each subsequent clinic visit
- •Agrees to consume only low polyphenols in the diet (nutritionists will counsel on high polyphenol fruits, vegetables to avoid, wine, beer, supplements, herbal extracts, and whole-grain based foods) 3 days prior to baseline and on test days (meal options and lists of foods to avoid will be provided to subjects by nutritionists)
- •Has given voluntary, written, informed consent to participate in the study
排除标准
- •BMI ≥ 30 kg/m2
- •Women who are pregnant, breastfeeding, or planning to become pregnant during the course of the trial.
- •Unstable medical conditions as determined by the Qualified Investigator
- •Use of natural health products containing turmeric or curcumin within 7 days prior to randomization and during the course of the study
- •Use of St Johns Wort 3 weeks prior to baseline and during the study
- •Subjects who are smokers
- •Subjects with current or history of gastrointestinal problems or disease
- •Metabolic, endocrine, or chronic diseases
- •Immunocompromised individuals such as subjects that have undergone organ transplantation or subjects diagnosed with human immunodeficiency virus (HIV)
- •Clinically significant abnormal lab results at screening (e.g. AST and/or ALT > 2 x ULN, and/or bilirubin > 2 x ULN) will be assessed by the Qualified Investigator
- •Subjects who have planned surgery during the course of the trial
- •History of or current diagnosis of any cancer (except for successfully treated basal cell carcinoma) diagnosed less than 5 years prior to screening. Subjects with cancer in full remission more than 5 years of diagnosis are acceptable.
- •History of gallbladder issues, hyperacidity, gastric/duodenal ulcers.
- •Prior use of prescription H2 blocker, proton pump inhibitor or blood sugar-lowering agents
- •Use of blood pressure medication
- •Subjects on restrictive dietary regimens
- •Blood donation in the last 2 months
- •History of blood/bleeding disorders or taking prescription blood thinners or anti-platelet therapy
- •Alcohol abuse (>2 standard alcoholic drinks per day) or drug abuse within the past 6 months
- •Use of medical marijuana
- •Clinically significant abnormal laboratory results at screening
- •Participation in a clinical research trial within 30 days prior to randomization
- •Allergy or sensitivity to study supplement ingredients or to any food or beverage provided during the study
- •Individuals who are cognitively impaired and/or who are unable to give informed consent
- •Any other condition which in the Investigator's opinion may adversely affect the subject's ability to complete the study or its measures or which may pose significant risk to the subject
研究组 & 干预措施
Dosing Sequence 1
Experimental
Proprietary Curcumin Formulation administered first, Unformulated Comparator Curcumin Product administered second
干预措施: Proprietary Curcumin Formulation (Dietary Supplement)
Dosing Sequence 1
Experimental
Proprietary Curcumin Formulation administered first, Unformulated Comparator Curcumin Product administered second
干预措施: Unformulated Comparator Curcumin Product (Dietary Supplement)
Dosing Sequence 2
Experimental
Unformulated Comparator Curcumin Product administered first, Proprietary Curcumin Formulation administered second
干预措施: Unformulated Comparator Curcumin Product (Dietary Supplement)
Dosing Sequence 2
Experimental
Unformulated Comparator Curcumin Product administered first, Proprietary Curcumin Formulation administered second
干预措施: Proprietary Curcumin Formulation (Dietary Supplement)
结局指标
主要结局
Curcumin AUC
时间窗: Time 0 to 48 hours
Area Under the Curve
Curcumin Tmax
时间窗: Time 0 to 48 hours
Time until maximum concentration
Curcumin Cmax
时间窗: Time 0 to 48 hours
Maximum Concentration
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Efficacy of Acute Intake of Ketones on Performance in Professional Road CyclistsKetosisKetoses, MetabolicNCT05294939Universidad Católica San Antonio de Murcia29
已完成
1 期
Phase 1 Pharmacokinetic Study of Minoxidil SL TabletsPharmacokineticNCT06679556Samson Clinical Operations Pty Ltd12
已完成
1 期
A Study to Evaluate Bioavailability, Food Effect, Safety and Tolerability of a Solid Dosage Formulation of JNJ-54861911 in Healthy Older Male ParticipantsHealthyNCT02260700Janssen Research & Development, LLC12
已完成
3 期
A Study to Evaluate Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Resected MelanomaMelanomaNCT05907122Amgen256
已完成
1 期
Pharmacokinetics and Safety of a Single Intravenous Infusion of BAY 79-4980Hemophilia ANCT00629837Bayer27